Quest for the right Drug
יופמירו 300 IOPAMIRO 300 (IOPAMIDOL)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Pharmacological properties : תכונות פרמקולוגיות
Pharmacodynamic Properties
5.1 Pharmacodynamic properties Pharmacotherapeutic category: Iodated, X-ray contrast media: Water-soluble, nephrotropic, low osmolar X-ray contrast media. ATC code: V08AB04 Iopamidol is a non-ionic radio-opaque hydrosoluble substance with strongly reduced toxicity and no teratogenic effects. Its use at doses 2 to 4 times higher than for clinical use provoked transient bradycardia and hypotension in dogs, followed by mild hypertension and increased respiratory frequency. Base values were returned in 2-4 minutes. The results of a prospective study with CT multilayer method indicate that the incidence of contrast nephropathy in patients with moderate or severe renal insufficiency (creatinine clearance between 10:59 mL/min/1.73m2) undergoing TC examination after intravenous administration of a dose equal to 40 g of iodine, was low and not significantly different with the nonionic monomer at low osmolality, iopamidol and with a nonionic iso-osmolar dimer. With iopamidol no cases of increased serum creatinine more than or equal to 0.5 mg/dL has been recorded, iopamidol and nonionic dimer caused increases in serum creatinine more than or equal to 25% of baseline values in the 3.9-4.0% of treated patients. The incidence of contrast nephropathy in patients undergoing cardioangiographic investigations with iopamidol is similar to that observed after administration of a nonionic iso-osmolar dimer.
Pharmacokinetic Properties
5.2 Pharmacokinetic properties Biotrasformation: In humans and animals iopamidol does not undergo detectable metabolic processes. Elimination: the vast majority is via renal route. In dogs, 93-95% of the administered dose was excreted renally and 0.5% through the biliary route in 7-10 hours. In humans, more than 90% of the dose is excreted by the urinary route in 24 hours. Blood half-life in the excretion phase (T ½ / B) is approximately 60 minutes in dogs and 90-120 minutes in humans. For intrathecal administration it will pass into the bloodstream, with peak reached in 90-150 min. and almost complete excretion in 24 hours.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף